DIASTAT ACUDIAL (diazepam) by Bausch + Lomb. Approved for benzodiazepine [epc]. First approved in 1997.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
DIASTAT ACUDIAL is a rectal gel formulation of diazepam, a benzodiazepine used for acute seizure management and epilepsy control. It delivers rapid anxiolytic and anticonvulsant effects via rectal absorption, providing a non-IV alternative for emergency seizure intervention.
Minimal Medicare Part D penetration and declining trend indicate a niche, mature product with limited commercial team expansion opportunities.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Worked on DIASTAT ACUDIAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDIASTAT ACUDIAL offers limited career growth given its LOE-approaching lifecycle, minimal commercial spending ($23K Part D), and lack of linked job openings. Roles on this product focus primarily on defensive market maintenance, reimbursement optimization, and managed transition—offering stability but not expansion.